Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-003 in chronic hepatitis B with HDV coinfection
CTR20211742Phase 2Terminated
- Sponsor
- Huahui Health
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Libevitug in Chronic Hepatitis B (CHB), hepatitis D (HDV), sponsored by Huahui Health. Started Jul 2021; status: terminated.
02
Drugs
Libevitug
03
Conditions
Chronic Hepatitis B (CHB)hepatitis D (HDV)
Beyond the preview
Go deeper on CTR20211742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211742.